Method of risk management for patients undergoing Natalizumab treatment
US7972775B2 · kind B2 · utility
5Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2006 |
| Grant date | Jul 5, 2011 |
| Priority date | — |
| Expiry date | Jul 1, 2027 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/285
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Progressive multifocal leukoencephalopathy (PML) has been identified in patients taking natalizumab (NMAB) for the treatment of multiple sclerosis (MS). This patent application provides a novel method of patient screening and monitoring intended to decrease the risk of PML and other opportunistic central nervous system (CNS) diseases in patients undergoing MS therapy with NMAB, and proposes a novel method of screening and monitoring intended to decrease the risk of opportunistic disease processes of the CNS during the treatment of other medical disorders with NMAB.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.